NCT04157114

MAP4343 Treatment for Alcohol Use Disorder

A Double-Blind, Randomized, Controlled Trial of MAP4343 Treatment, a Ligand of the Neurospecific Microtubule Associated Protein-2, for Alcohol Use Disorder

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: The Scripps Research Institute · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This is a Phase 2, single-site, randomized, double-blind, placebo-controlled, proof-of-concept (POC) study involving 6 weeks of MAP4343 in conjunction with 6 weeks of manual-guided counseling, with 2 follow-up visits at 1 week and 1 month post-treatment.

Conditions

• Alcohol Use Disorder

Interventions

Type	Name	Description
DRUG	MAP4343	Subjects will receive daily oral doses of MAP4343 for 6 weeks in conjunction with 6 weeks of manual-guided counseling
DRUG	Placebo	Subjects receive matched placebo for 6 weeks in conjunction with 6 weeks of manual-guided counseling
BEHAVIORAL	Standardized behavioral counseling	Subjects receive manually-guided counseling 1 time per week for a 6 week duration

Timeline

• Start date: 2021-12-01
• Primary completion: 2022-12-01
• Completion: 2022-12-01
• First posted: 2019-11-08
• Last updated: 2022-03-11

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study